Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
ReutersFeb 24, 2026 1:02 PM
Feb 24 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:
RADIOPHARM THERANOSTICS DOSES FIRST PATIENT IN PHASE 1/2A CLINICAL STUDY OF BETABART (RV-01)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.TradingKey
4 hours ago
Tesla Stock Outlook: Why 2026 Could Be the Year of the Tesla Robotaxi
TradingKey - The concept of autonomous mobility for Tesla(TSLA) has gone from a projection of the far away future to a vital part of its overall long-term growth strategy.TradingKey
6 hours ago
International Copper Prices Rise for 7 Straight Months; Will Bull Market Continue in 2026?
TradingKey - As the "king of industrial metals," every fluctuation in international copper prices impacts the nerves of global investors. In early 2026, international copper prices continued to rise, extending the upward trend from 2025 and reaching a new high above $14,500, marking seven consecutive months of gains. Meanwhile, London Metal Exchange (LME) copper prices have climbed from $7,800 per tonne in July 2025 to over $9,000 per tonne today.TradingKey
Mon, Feb 23
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
